u-50488 and Brain-Damage--Chronic

u-50488 has been researched along with Brain-Damage--Chronic* in 1 studies

Other Studies

1 other study(ies) available for u-50488 and Brain-Damage--Chronic

Article	Year
Potential protection by a specific kappa-opiate agonist U-50488H against membrane failure in acute ischemic brain. Neurologia medico-chirurgica, 1993, Volume: 33, Issue:3 The effects of a novel opioid kappa-receptor agonist U-50488H on Na(+)-K(+)-adenosine triphosphatase (ATPase) activity and regional cerebral blood flow (rCBF) were studied in the acute ischemic brain of rats after middle cerebral artery (MCA) occlusion. Administration of U-50488H 15 minutes prior to MCA occlusion attenuated ischemic reduction in Na(+)-K(+)-ATPase activity 15 minutes after MCA occlusion. The effect was statistically significant at a dosage of 30 mg/kg, but not at lower doses (0.3 and 3 mg/kg). There was no effect on rCBF before MCA occlusion, and the decreased flow after occlusion was enhanced with a significant fall in systemic blood pressure at a dosage of 30 mg/kg. These results indicate that U-50488H has therapeutic potential in cerebral ischemia by mechanisms other than improvement in CBF. Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antihypertensive Agents; Blood Pressure; Brain; Brain Damage, Chronic; Brain Ischemia; Male; Pyrrolidines; Rats; Rats, Wistar; Receptors, Opioid, kappa; Regional Blood Flow; Sodium-Potassium-Exchanging ATPase; Synaptic Membranes	1993

Article

Year

Potential protection by a specific kappa-opiate agonist U-50488H against membrane failure in acute ischemic brain.

Neurologia medico-chirurgica, 1993, Volume: 33, Issue:3

The effects of a novel opioid kappa-receptor agonist U-50488H on Na(+)-K(+)-adenosine triphosphatase (ATPase) activity and regional cerebral blood flow (rCBF) were studied in the acute ischemic brain of rats after middle cerebral artery (MCA) occlusion. Administration of U-50488H 15 minutes prior to MCA occlusion attenuated ischemic reduction in Na(+)-K(+)-ATPase activity 15 minutes after MCA occlusion. The effect was statistically significant at a dosage of 30 mg/kg, but not at lower doses (0.3 and 3 mg/kg). There was no effect on rCBF before MCA occlusion, and the decreased flow after occlusion was enhanced with a significant fall in systemic blood pressure at a dosage of 30 mg/kg. These results indicate that U-50488H has therapeutic potential in cerebral ischemia by mechanisms other than improvement in CBF.

Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; Antihypertensive Agents; Blood Pressure; Brain; Brain Damage, Chronic; Brain Ischemia; Male; Pyrrolidines; Rats; Rats, Wistar; Receptors, Opioid, kappa; Regional Blood Flow; Sodium-Potassium-Exchanging ATPase; Synaptic Membranes

1993